KRAS and TP53 co-mutation predicts benefit of immune checkpoint blockade in lung adenocarcinoma.
Budczies J, Romanovsky E, Kirchner M, Neumann O, Blasi M, Schnorbach J, Shah R, Bozorgmehr F, Savai R, Stiewe T, Peters S, Schirmacher P, Thomas M, Kazdal D, Christopoulos P, Stenzinger A.
Budczies J, et al. Among authors: peters s.
Br J Cancer. 2024 Jun 12. doi: 10.1038/s41416-024-02746-z. Online ahead of print.
Br J Cancer. 2024.
PMID: 38866964